에 대한 최신 뉴스 Qiagen (NYSE:QGEN) 주식

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

News

QIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States

QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technologyQuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide
<ul>
<li>QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology</li>
<li>QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide</li>
</ul>

QIAGEN Files Lawsuit To Protect QuantiFERON Technology Amid Tuberculosis Testing Patent Dispute

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowered the price target from $52 to $42. Qiagen shares closed at $40.01 on Tuesday. <a href="https://www.benzinga.com/quote/QGEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Catherine Schulte downgraded Bio-Techne Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Outperform to Neutral and lowered the price target from $88 to $68. Bio-Techne shares closed at $65.29 on Tuesday. <a href="https://www.benzinga.com/quote/TECH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss downgraded Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Overweight to Equal-Weight and lowered the price target from $330 to $275. Workday shares closed at $265.72 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Kyle Bauser downgraded the rating for Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral and slashed the price target from $23 to $18. Tactile Systems shares closed at $17.86 on Tuesday. <a href="https://www.benzinga.com/quote/TCMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Kristen Kluska downgraded Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and lowered the price target from $57 to $36. Supernus Pharmaceuticals shares closed at $39.75 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="427" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png" alt="" class="wp-image-788949" style="width:460px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-1024x427.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-300x125.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168-768x320.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19084320/image-168.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CRVO

SUPN

TCMD

TECH

WDAY

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Baird analyst Catherine Schulte downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Outperform to Neutral and lowers the price target from $52 to $42.

Price Target

Baird Downgrades Qiagen to Neutral, Lowers Price Target to $42

UBS analyst John Sourbeer maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Neutral and lowers the price target from $50 to $48.

UBS Maintains Neutral on Qiagen, Lowers Price Target to $48

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Qiagen Earnings Review: Q4 Summary

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported its Q4 earnings results on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Qiagen Q4 Earnings Report: What Investors Need to Know

The Q4 earnings report for Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) was released on Wednesday, February 5, 2025 at 04:05 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Qiagen Q4 Earnings

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) announced its Q4 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.03, leading to a 1.0% increase share price change the next day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Qiagen: Q4 Earnings Insights

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) released its Q4 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Qiagen missed estimated earnings by -2.0%, reporting an EPS of $0.61 versus an estimate of $0.62.
Revenue was up $11.84 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.03 in the last quarter, resulting in a 1.0% increase share price change the following day.
Here's a look at Qiagen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.54</td>
<td>0.51</td>
<td>0.44</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.55</td>
<td>0.46</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>491.75M</td>
<td>494.49M</td>
<td>457.33M</td>
<td>501.28M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>502.00M</td>
<td>496.00M</td>
<td>458.80M</td>
<td>509.16M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Qiagen <a href="https://www.benzinga.com/quote/QGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Qiagen Q4

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced that the German Federal Patent Court (Bundespatentgericht) has ruled in its favor in a patent dispute against SD Biosensor, reaffirming the validity of an important patent protecting key innovations in its QuantiFERON technology.
This ruling underscores the strength of QIAGEN's QuantiFERON intellectual property portfolio and protects the scientific advancements that have made QuantiFERON-TB Gold Plus the global standard for latent TB testing.

Biotech

Legal

General

QIAGEN Wins German Patent Dispute Against SD Biosensor, Validating Key QuantiFERON Technology Innovations

<ul>
<li>Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS</li>
<li>Return of approximately $300 million – maximum approved by shareholders – set to be completed in late January 2025</li>
<li>Builds on approximately $300 million returned to shareholders in early 2024 as part of commitment to return at least $1 billion through end-2028</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.
QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase. Together, these two programs represent approximately $600 million of a commitment to return at least $1 billion to shareholders by the end of 2028 (absent M&amp;A opportunities).

Buybacks

Qiagen Announces $300M Capital Return Via Synthetic Share Repurchase By January 2025; Follows $300M Returned In Early 2024, Aiming For $1B Total By 2028. Plan Involves 3% Reduction In Issued Shares, Enhancing EPS

QIAGEN has decided to implement the maximum USD300 million value of the mandate given at the Annual General Meeting in June 2024, where shareholders gave virtually unanimous approval for the related resolutions. This approach is designed to return cash to shareholders in a more efficient way than through a traditional open-market repurchase program. It would also enhance earnings per share (EPS) through the reduction in outstanding shares. The synthetic share repurchase will become effective on January 28, 2025, and will be settled in line with market convention in the subsequent days

Qiagen Said Sunday, It Will Return ~$300M To Shareholders Through A Synthetic Share Repurchase

<ul>
<li>QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets</li>
<li>No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit</li>
<li>New QIAcuity digital PCR capabilities helps make lab work more productive and cost-efficient through savings on time, reagents consumption and use of precious sample materials</li>
</ul>

QIAGEN Enhances QIAcuity Digital PCR With High-Order Multiplexing For Simultaneous Detection Of Up To12 Targets

<ul>
<li>New QIAstat-Dx Gastrointestinal Panel 2 Mini B&amp;V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions</li>
<li>QIAGEN the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients</li>
<li>QIAstat-Dx Rise higher-capacity instrument version to be submitted in early 2025 for U.S. regulatory clearance, builds on groundbreaking 2024 clearances of four QIAstat-Dx Panels</li>
</ul>

Reported Earlier, QIAGEN Gains FDA Clearance For QIAstat-Dx Mini Gastrointestinal Panel, Supporting Year-Round Outpatient Care

Morgan Stanley analyst Steve Beuchaw downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Overweight to Equal-Weight and lowers the price target from $50 to $48.

Morgan Stanley Downgrades Qiagen to Equal-Weight, Lowers Price Target to $48

<ul>
<li>Ingenuity Pathway Analysis Interpret extends analysis capabilities of human-curated knowledge base with AI technology</li>
<li>AI-extension highlights key biological elements at work and provides summarized results and interpretations in a sharable web document, speeding up interpretation</li>
<li>Ingenuity Pathway Analysis Interpret unlocks the full potential of biological data by streamlining interpretation process and delivering actionable insights for experiments</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Leveraging AI technology, IPA Interpret helps distill complex differential expression analyses into actionable insights, helping researchers understand which genes are involved in a disease, a biological process or a response to a drug or environmental condition.
IPA, which forms the foundation of IPA Interpret, has over 50,000 citations and a high-quality, manually curated knowledge base. This widely recognized platform structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs chemicals, and other objects. With IPA's curated knowledge base, scientists can confidently predict and validate novel target-disease and drug-disease relationships.
By combining this extensive knowledge with advanced analyses and AI algorithms, IPA Interpret now automatically analyzes, compares, and contextualizes complex gene expression datasets available in IPA, identifying key biological processes, pathways, and networks, in a streamlined web-page report.

QIAGEN Launches AI-Extension Of Ingenuity Pathway Analysis For Automatic Interpretation Of Biological Data

Jefferies analyst Tycho Peterson assumes Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Buy rating and raises Price Target to $54.

Initiation

Jefferies Assumes Qiagen at Buy, Raises Price Target to $54

<ul>
<li>EZ2 Connect for automated nucleic acid purification has reached over 1,000 placements worldwide, contributing to a global installed base of more than 5,500 EZ series instruments</li>
<li>Comprehensive portfolio of EZ2 Connect automated kits provides research and clinical labs with more time for in-depth analyses rather than manual processing
<ul>
<li>Launch of EZ2 PowerFecal Pro DNA/RNA Kit expands portfolio into gut microbiome research, builds on EZ2 Connect kits for applications such as diagnostics, genomics and cancer research, molecular epidemiology and forensics</li>
</ul>
</li>
</ul>

QIAGEN Achieves Milestone With Over 1,000 Placements Of EZ2 Connect Sample Preparation Instrument

Press Releases

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

QIAGEN delivers solid Q4 2024 growth ahead of outlook

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

Baird

Morgan Stanley

Jefferies

Wolfe Research

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" target="_blank" rel="noopener" data-google-interstitial="false">재무 실적</a>을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다.
애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.
<h3 class="wp-block-heading">‘주식 선택자의 해&#8217;: S&amp;P 500에서 10% 상승</h3>
골드만삭스의 애널리스트들은 2024년을 &#8220;주식 선택자의 해&#8221;라고 부르며, 변동성이 큰 실적 환경에서 선택적 투자의 중요성을 강조했다.
이 투자은행의 최신 전망에 따르면, 평균 S&amp;P 500 주식은 향후 12개월 동안 10%의 상승 잠재력을 가질 수 있다.
&#8220;우리는 반등 가능성을 보고 있다&#8221;고 마샬이 그의 노트에서 언급했다. &#8220;옵션 시장의 방향성 포지셔닝이 균형을 이루고 있어, 지난 분기 이맘때보다 훨씬 나은 설정이다.&#8221;
또한 이 애널리스트들은 최근 헤지 펀드와 소매 트레이더들 모두의 옵션 시장 활동이 감소하여, 투자자들이 3분기 실적 보고서와 다가오는 미국 선거를 준비하면서 &#8220;관망하는(wait-and-see)&#8221; 태도를 취하고 있음을 나타냈다.
<h3 class="wp-block-heading">실적 시즌의 변동성은 여전히 높다</h3>
골드만삭스는 실적 이벤트를 둘러싼 개별 주식의 변동성이 14년 만에 최고 수준에 있다고 강조했다.
인공지능(AI), 금리 그리고 다가오는 선거와 같은 주요 시장 논쟁이 이 추세를 주도하고 있으며, 이는 연말까지 계속될 것으로 예상된다.
&#8220;우리는 실적 발표일의 주가 변동이 여전히 높을 것으로 예상하며, 이는 시장의 주요 논쟁들이 주식 공간에서 승자와 패자를 만들어내기 때문이다,&#8221;라고 이 노트에 추가했다.
이러한 높은 변동성 속에서, 이 회사는 옵션 기반 전략을 계속 추천하며, 투자자들에게 실적 이벤트 전 옵션을 매수하고 실적 기간 사이에 옵션을 매도하여 가격 변동을 활용할 것을 권장했다.
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 긍정적으로 평가한 18개 주식</h3>
골드만삭스의 애널리스트들은 실적 조정이 긍정적으로 작용할 수 있다고 믿는 18개의 주식을 선정했다. 이 주식들은 에너지, 금융, 헬스케어, 기술 등 다양한 부문에 걸쳐 있다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>갭 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>소비재</td>
<td>11월 15일</td>
</tr>
<tr>
<td>퍼미안 리소스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>에너지</td>
<td>11월 7일</td>
</tr>
<tr>
<td>씨티그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>금융</td>
<td>10월 15일</td>
</tr>
<tr>
<td>싱크로니 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>금융</td>
<td>10월 16일</td>
</tr>
<tr>
<td>암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>헬스케어</td>
<td>10월 23일</td>
</tr>
<tr>
<td>머크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>헬스케어</td>
<td>10월 31일</td>
</tr>
<tr>
<td>퀴아젠 NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>헬스케어</td>
<td>10월 30일</td>
</tr>
<tr>
<td>AZEK 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>산업재</td>
<td>11월 29일</td>
</tr>
<tr>
<td>ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>11월 1일</td>
</tr>
<tr>
<td>브로드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>12월 6일</td>
</tr>
<tr>
<td>델 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>11월 25일</td>
</tr>
<tr>
<td>클라비요 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>먼데이닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>11월 13일</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>11월 21일</td>
</tr>
<tr>
<td>스노우플레이크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>11월 29일</td>
</tr>
<tr>
<td>토스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셈프라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>유틸리티</td>
<td>11월 4일</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">골드만삭스가 3분기 실적에 대해 비관적으로 평가한 7개 주식</h3>
반대로, 이 투자은행은 3분기 실적에서 하향 조정의 영향을 받을 것으로 예상되는 7개 주식을 선정하여 투자자들에게 주의할 것을 권고했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>실적 발표일</th>
</tr>
</thead>
<tbody>
<tr>
<td>초이스호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>소비재</td>
<td>11월 7일</td>
</tr>
<tr>
<td>셰니에르 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>에너지</td>
<td>11월 1일</td>
</tr>
<tr>
<td>야누스 헨더슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>금융</td>
<td>10월 31일</td>
</tr>
<tr>
<td>라이온델바젤 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>소재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크로락스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>소비재</td>
<td>11월 1일</td>
</tr>
<tr>
<td>크래프트 하인즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>소비재</td>
<td>10월 30일</td>
</tr>
<tr>
<td>업스타트 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>11월 7일</td>
</tr>
</tbody>
</table>
</figure>
다음 글 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">연준의 굴스비가 인플레이션 상승을 경시하며, 경제학자들은 11월 금리 인하 발표에 대한 입장을 고수합니다.</a></li>
</ul>
이미지는 Midjourney를 통해 인공지능으로 생성되었습니다.

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 '주식 선택자의 해'

Comments

Qiagen

뉴스

에 대한 최신 뉴스 Qiagen (NYSE:QGEN) 주식

금요일, 10월 11, 2024

뉴스

파트너 / 기고자

벤징가 글로벌